SUPN

#1841
Supernus Pharmaceuticals, Inc. - Common Stock
43.7 3 USD
-0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
43.73
43.73
Intervallo Annuale
42.45
59.68
Variazione giornaliera
-1.04%
Variazione Mensile
-3.23%
Variazione di 6 mesi
-19.00%
Variazione Annuale
-19.02%
Chiusura Precedente
44.1 9
Open
43.7 3
Minimo
43.7 3
Massimo
43.7 3
Volume
115
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2025

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Supernus Pharmaceuticals, Inc. (SUPN) covers the date of June 16, 2025. The filing documents the results of the Company's Annual Meeting of Stockholders held on that date. The definitive proxy statement for this meeting was previously filed on April 30, 2025. As of the record date on April 22, 2025, there were 55,989,623 shares of common stock outstanding and entitled to vote.

Financial Metrics

This filing is a corporate governance report regarding stockholder votes and does not contain financial performance data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

There are no material financial changes reported in this document. The filing details the successful ratification of corporate governance matters, including the election of directors and the approval of executive compensation.

Outlook, Risks, and Management Commentary

The filing contains no management commentary on future outlook, risks, contingencies, or unusual items. The primary content is the tabulation of votes for three proposals:

  • Proposal 1 (Election of Class I Directors): Both nominees, Carolee Barlow, M.D., Ph.D., and Jack A. Khattar, received significant majority support with over 46 million votes "For" each.
  • Proposal 2 (Executive Compensation): The non-binding advisory vote on executive compensation was approved with 45,796,936 votes "For" versus 1,701,777 votes "Against."
  • Proposal 3 (Auditor Ratification): The appointment of KPMG LLP as the independent public accounting firm for the fiscal year ending December 31, 2025, was ratified with 49,230,498 votes "For."

Key Facts for Investor Verification

  • Verify the total number of shares outstanding (55,989,623) against the most recent 10-Q or 10-K to confirm no significant share issuances or buybacks occurred between the record date and the meeting.
  • Confirm the tenure of the newly elected Class I Directors (Carolee Barlow and Jack A. Khattar) extends until the 2028 Annual Meeting.
  • Note that KPMG LLP has been ratified as the auditor for the fiscal year ending December 31, 2025.
  • Review the previously filed proxy statement (dated April 30, 2025) for detailed context on the executive compensation package approved in Proposal 2.

Notizie